Fig 7. Meta-analysis of the overall treatment-related adverse events associated with pembrolizumab.
Subgroup analysis of patients treated with different doses of pembrolizumab revealed a dose-dependent increase in adverse events.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.